Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $291
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Overweight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $236 to $291.
June 25, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Gena Wang maintains an Overweight rating on Alnylam Pharmaceuticals and raises the price target from $236 to $291.
The raised price target and maintained Overweight rating from a reputable analyst at Barclays is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100